Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

Alison F. Munro, Annette Bartels, Eva Balslev, Christopher J. Twelves, David A Cameron, Nils Brünner, John Ms Bartlett

    4 Citationer (Scopus)

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?'. Sammen danner de et unikt fingeraftryk.

    Medicin og biovidenskab